WIVR investigators Dr. Lowell Chang and Dr. Erik Bieging, along with health coach Natalie Coombs-Vaterlaus, implemented the VALOR-QI program within the VA Salt Lake City Health Care System and engaged 138 Veterans over two years.

The U.S. Food and Drug Administration (FDA) recently approved an on-body injector for Sarclisa Escena® (isatuximab-irfc), making it the first anticancer therapy in the United States available through this type of wearable device. WIVR is proud to have served as a participating site for the IRAKLIA Phase 3 clinical trial that contributed to the evidence supporting this approval.

Researchers from the U.S. Department of Veterans Affairs (VA), led by Eamonn Kennedy, PhD, analyzed the clinical records of 10,000 veterans to examine whether military occupational blast and impulse exposure (MOBE) was associated with documented anger, aggression, and violence (AAV).

Led by Erin Bouldin, PhD, MPH, a VA research team has published a new protocol paper in JMIR Research Protocols exploring how post-9/11 Veterans at higher risk of Alzheimer’s and related dementias use home and community-based services (HCBS). The goal of the study is to understand Veterans’ and caregivers’ needs, preferences, and barriers to these services, ultimately identifying ways to improve support.